Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation.

Lung cancer (Amsterdam, Netherlands) - 1 Jan 2015

Suzuki Mikiko, Shiraishi Kouya, Yoshida Akihiko, Shimada Yoko, Suzuki Kenji, Asamura Hisao, Furuta Koh, Kohno Takashi, Tsuta Koji

Abstract excerpt

BACKGROUND: Dysregulation of HER2 signaling pathways results in tumor progression in several types of carcinomas. The aim of the current study is to identify clinicopathological characteristics of HER2-mutated non-small cell lung carcinomas (NSCLCs) in conjunction with HER2 protein expression, gene amplification, and phosphorylation. PATIENTS AND METHODS: We investigated 1275 patients including 1055...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Gene Amplification

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Rearrangement

Share to Proto-Oncogene Proteins B-raf

Share to ras Proteins

Share to Receptor, ErbB-2

Share to Receptor Protein-Tyrosine Kinases

Share to Tumor Burden

Source

Identifiers

PMID: 25468202
DOI: 10.1016/j.lungcan.2014.10.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation.PMID 25468202Read ↗

Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non-Small Cell Lung Cancer: Implications for Precision Medicine.Semantic proximity Read ↗

The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.Semantic proximity Read ↗

Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas.Semantic proximity Read ↗

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.Semantic proximity Read ↗

Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations.Semantic proximity Read ↗

Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features.Semantic proximity Read ↗

HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.Semantic proximity Read ↗

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.Semantic proximity Read ↗

Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number GainsSemantic proximity Read ↗

Non-amplification genetic alterations of HER2 gene in non-small cell lung carcinoma.Semantic proximity Read ↗

Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.Semantic proximity Read ↗

Targeting HER2 in the treatment of non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.